Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Androgen Receptor Predicts First and Multiple Recurrences in Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Androgen Receptor Predicts First and Multiple Recurrences in Non-Muscle Invasive Urothelial... The aim of this study is to investigate the role of androgen receptor (AR) expression on clinicopathologic characteristics, first recurrence free survival (RFS), progression free survival (PFS) and multiple recurrences in non-muscle invasive bladder cancer (NMIBC). AR expression in 40 paraffin-embedded specimens of primarily diagnosed NMIBC after transurethral resection was examined by immunohistochemistry using a monoclonal AR antibody. Associations between AR expression and clinicopathologic features and prognosis were statistically assessed. Multivariate Cox proportional hazards model was applied for evaluating predictive factors on RFS and PFS. For multiple recurrences, we used the Andersen-Gill model. AR was positive in 20/40 (50%) cases. Twenty-three patients (57.5%) had no recurrence, 10 (25.0%) had one recurrence, and 7 (17.5%) experienced more than one recurrence. AR expression and clinicopathologic features were not significantly correlated (P >0.05). Univariate analyses showed that AR expression was significantly associated with RFS and PFS (P <0.05). Via multivariate analyses, positive AR expression was significantly associated with lower risk of first recurrence (hazard ratio (HR) = 0.265; 95% confidence interval (95% CI) = 0.084–0.829; P = 0.022). Multivariate analysis of PFS was not feasible in our cohort. Using the multivariate Andersen-Gill model, positive AR expression in the primary tumor was an independent factor predicting lower risk of multiple recurrences (HR = 0.387, 95% CI = 0.161–0.927, P = 0.033). Androgen receptor expression is associated with first and multiple recurrences in NMIBC. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pathology & Oncology Research Springer Journals

Androgen Receptor Predicts First and Multiple Recurrences in Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Download PDF
8 pages

Loading next page...
 
/lp/springer_journal/androgen-receptor-predicts-first-and-multiple-recurrences-in-non-KiRDUd7qdu
Publisher
Springer Journals
Copyright
Copyright © 2018 by Arányi Lajos Foundation
Subject
Biomedicine; Cancer Research; Oncology; Pathology; Immunology; Biomedicine, general
ISSN
1219-4956
eISSN
1532-2807
DOI
10.1007/s12253-018-0431-7
Publisher site
See Article on Publisher Site

Abstract

The aim of this study is to investigate the role of androgen receptor (AR) expression on clinicopathologic characteristics, first recurrence free survival (RFS), progression free survival (PFS) and multiple recurrences in non-muscle invasive bladder cancer (NMIBC). AR expression in 40 paraffin-embedded specimens of primarily diagnosed NMIBC after transurethral resection was examined by immunohistochemistry using a monoclonal AR antibody. Associations between AR expression and clinicopathologic features and prognosis were statistically assessed. Multivariate Cox proportional hazards model was applied for evaluating predictive factors on RFS and PFS. For multiple recurrences, we used the Andersen-Gill model. AR was positive in 20/40 (50%) cases. Twenty-three patients (57.5%) had no recurrence, 10 (25.0%) had one recurrence, and 7 (17.5%) experienced more than one recurrence. AR expression and clinicopathologic features were not significantly correlated (P >0.05). Univariate analyses showed that AR expression was significantly associated with RFS and PFS (P <0.05). Via multivariate analyses, positive AR expression was significantly associated with lower risk of first recurrence (hazard ratio (HR) = 0.265; 95% confidence interval (95% CI) = 0.084–0.829; P = 0.022). Multivariate analysis of PFS was not feasible in our cohort. Using the multivariate Andersen-Gill model, positive AR expression in the primary tumor was an independent factor predicting lower risk of multiple recurrences (HR = 0.387, 95% CI = 0.161–0.927, P = 0.033). Androgen receptor expression is associated with first and multiple recurrences in NMIBC.

Journal

Pathology & Oncology Research – Springer Journals

Published: Jun 3, 2018

References

  • Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
    Sylvester, RJ
  • Sex and racial differences in bladder cancer presentation and mortality in the US
    Scosyrev, E
  • Sex differences in bladder cancer pathology and survival: analysis of a population-based cancer registry
    Zaitsu, M
  • Unexplained excess risk of bladder cancer in men
    Hartge, P
  • Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit
    Rosenzweig, BA
  • Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition
    Jing, Y
  • Promotion of bladder cancer development and progression by androgen receptor signals
    Miyamoto, H
  • Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor
    Hsu, JW
  • Androgen receptor is a potential therapeutic target for bladder cancer
    Wu, JT
  • The emerging role of the androgen receptor in bladder cancer
    Lombard, AP; Mudryj, M
  • Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer
    Boorjian, S
  • Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer
    Kauffman, EC
  • Role of steroid hormone receptors in formation and progression of bladder carcinoma: a case-control study
    Mashhadi, R
  • Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study
    Mir, C
  • Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder
    Miyamoto, H
  • Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression
    Tuygun, C
  • Prognostic value of sex-hormone receptor expression in non-muscle-invasive bladder cancer
    Nam, JK
  • Evaluation of multiple recurrence events in superficial bladder cancer patients treated with intravesical bacillus Calmette-Guerin therapy using the Andersen-Gill’s model
    Takashi, M
  • Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors
    Yan, Y
  • Androgen deprivation therapy prevents bladder cancer recurrence
    Izumi, K
  • Association between smoking and risk of bladder cancer among men and women
    Freedman, ND
  • The 2004 WHO classification of bladder tumors: a summary and commentary
    Montironi, R; Lopez-Beltran, A
  • Cox’s regression model for counting processes: a large sample study
    Andersen, PK; Gill, RD
  • Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: a meta-analysis of immunohistochemical studies
    Ide, H; Inoue, S; Miyamoto, H
  • The role of the androgen receptor in the development and progression of bladder cancer
    Li, Y; Izumi, K; Miyamoto, H
  • The expression of bcl-2 and bcl-6 protein in normal and malignant transitional epithelium
    Lin, Z
  • Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer
    Amirghofran, Z; Monabati, A; Gholijani, N
  • Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy
    Shiota, M
  • Finasteride reduces risk of bladder cancer in a large prospective screening study
    Morales, EE
  • Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide
    Haapala, K
  • Androgen receptor mutations in high-grade prostate cancer before hormonal therapy
    Thompson, J
  • Microsatellite instability in bladder cancer
    Gonzalez-Zulueta, M
  • CAG repeats in the androgen receptor gene are shorter in patients with pulmonary, esophageal or bladder carcinoma and longer in women with uterine leiomyoma
    Teng, XY
  • Androgen receptor gene polymorphism may affect the risk of urothelial carcinoma
    Liu, CH
  • Somatic mutation of the androgen receptor gene is not associated with transitional cell carcinoma: a “negative” study by whole-exome sequencing analysis
    Wu, S